1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Liaoning Chengda Biotechnology Co. Ltd. Class A

Liaoning Chengda Biotechnology Co. Ltd. Class A

SSSE:688739
20.00
CNY
-0.20
(-0.99%)
8.12BMarket Cap
Oct 30Next Earn
Liaoning Chengda Biotechnology Co. Ltd. Class A
SSE:688739
(Shanghai Stock Exchange)

Recent

price

20.00

P/E

ratio

- -

div

yld

0.51%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.74
2.36
2.6
2.62
2.77
3.4
3.7
4.47
5.32
5.47
4.35
4.21
4.06
3.38
- -
Revenue per Share
1.38
1.12
1.23
1.27
1.23
1.48
1.67
1.86
2.45
2.34
1.71
1.12
0.83
0.32
- -
Basic EPS, GAAP
0.02
0.97
1.71
1.29
1.37
1.61
1.42
0.7
1.79
-0.01
0.08
0.3
0.34
0.08
- -
Free Cash Flow per Basic Share
0.63
0.91
1.01
1
0.5
1
0.5
0.6
0.6
- -
1
1
0.8
0.8
0.1
Dividend per Share
4.12
4.34
4.56
4.82
6.24
6.73
7.87
9.14
10.99
22.46
23.17
23.05
22.96
22.46
22.42
Book Value per Share
3.75
3.95
4.18
4.45
6
6.49
7.53
8.8
10.65
21.98
22.32
21.75
21.15
20.53
20.46
Tangible Book Value per Share
359
361
360
360
372
376
375
375
375
381
418
416
413
412
404
Basic Weighted Avg Shares
985
851
937
943
1,030
1,276
1,391
1,677
1,996
2,088
1,815
1,750
1,676
1,390
- -
Sales/Revenue/Turnover
63.47
54.73
53.98
55.07
56.3
54.39
51.35
46.95
49.5
49.22
42.89
33.87
27.06
14.17
- -
Operating Margin (%)
45
53
67
66
68
47
53
68
65
116
121
125
172
179
- -
Depreciation Expense
496
404
442
458
457
556
627
698
918
892
714
466
343
132
- -
Net Income, GAAP
14.99
15.23
15.24
15.52
15.93
15.24
14.74
15.06
13.62
13.43
14.8
19.16
14.94
22.3
- -
Effective Tax Rate (%)
50.36
47.48
47.22
48.52
44.39
43.56
45.08
41.65
46.01
42.74
39.34
26.62
20.45
9.48
- -
Profit Margin (%)
888
928
1,012
1,079
1,674
1,869
2,256
2,317
2,815
7,509
7,433
6,892
6,690
6,486
6,506
Working Capital
49
- -
- -
- -
- -
- -
- -
- -
26
22
17
15
10
5
2
LT Debt
1,545
1,625
1,707
1,805
2,340
2,521
2,951
3,425
4,118
9,352
9,650
9,599
9,562
9,354
9,339
Total Equity
- -
24.45
25.14
24.98
22.36
23.8
23.67
22.68
25.06
13.19
7.55
4.87
3.63
1.42
- -
Return on Invested Capital (%)
- -
24.68
26.06
25.94
21.97
22.81
22.88
21.91
24.25
13.22
7.51
4.84
3.59
1.4
- -
Return on Capital (%)
- -
25.5
26.56
26.06
22.06
22.87
22.91
21.91
24.35
13.25
7.52
4.84
3.58
1.39
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
5
5
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
416
416
416
Market Capitalization
10,728
10,253
8,117

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,787
6,721
6,782
Cash, Cash Equivalents & STI
5,215
5,091
5,125
Accounts Receivable, Net
1,049
1,050
1,158
Inventories
474
472
459
Total Current Liabilities
301
236
276
Payables & Accruals
- -
- -
- -
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.79%
25.44%
-2.18%
Free Cash Flow
-165.72%
-355.72%
-76.33%
Net Income, GAAP
-6.84%
-29.11%
-61.56%
Sales/Revenue/Turnover
4.83%
-6.66%
-17.06%
Total Cash Common Dividend
- -
- -
-0.04%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
365
516
422
374
1,676
2025
358
348
- -
294
1,390
2026
273
404
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.34
0.27
0.03
0.83
2025
0.17
0.12
- -
-0.08
0.32
2026
- -
0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.8
2025
- -
- -
- -
- -
0.8
2026
- -
0.1
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Liaoning Chengda Biotechnology Co., Ltd. is a China-based biopharmaceutical enterprise primarily engaged in the research, development, manufacturing, and commercialization of human vaccines and immunobiological products. Founded in 2002 and headquartered in Shenyang, Liaoning Province, the company operates as a subsidiary of Liaoning Cheng Da Co., Ltd. and trades on the Shanghai Stock Exchange Science and Technology Innovation Board. The company focuses on prophylactic biopharmaceuticals, leveraging proprietary high-density microcarrier Vero cell culture platforms and modern purification technologies to produce high-purity inactivated viral vaccines. Its core commercial product portfolio comprises freeze-dried human rabies vaccines (Vero cell) marketed under the Speeda brand for pre-exposure and post-exposure prophylaxis; inactivated Japanese encephalitis vaccines (Vero cell) sold under the Meiweijia brand for pediatric and adult immunization against the Japanese encephalitis virus; live attenuated varicella vaccines for chickenpox prevention; and quadrivalent split-virion influenza vaccines for seasonal protection against influenza A and B viruses. In addition, the company actively develops a pipeline of next-generation biologics, including 13-valent pneumococcal conjugate vaccines (PCV13), bivalent and nonavalent human papillomavirus (HPV) vaccines, recombinant shingles vaccines, and combination pediatric vaccines. The company supplies public health authorities across all provincial-level administrative regions in mainland China through municipal and county-level Centers for Disease Control and Prevention (CDCs), while exporting products to more than thirty countries and regions across Asia, Africa, and Latin America. In recent developments, the company has expanded its manufacturing and quality control capabilities with automated production lines and cold-chain logistics facilities at its Shenyang and Benxi industrial bases; formed strategic collaborative research agreements with domestic and international biomedical research institutions to advance mRNA and recombinant protein vaccine technologies; and pursued World Health Organization (WHO) prequalification alongside overseas regulatory registrations to accelerate expansion into global emerging markets.